Results showed patients in the encorafenib/cetuximab plus FOLFOX arm had statistically significant improvement in objective response rate compared with those in the standard-of-care arm (60.9% vs.

Researchers conducted a meta-analysis of studies to explore the efficacy and safety of pembrolizumab alone and in combination with chemotherapy for the treatment of gastric and GEJ cancers.